IR Portal for Affitech
OMX Copenhagen: AFFI.CO
Seneste Kurs: 0,18
-5,26
Branche: Sundhed
RESSOURCER
Senest opdateret 30/12 2011
VIRKSOMHEDSBESKRIVELSE:
Affitech ASis a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway.
The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech’s premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company´s proprietary product candidates were generated by CBAS™.
Further information is available at www.affitech.com.
The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech’s premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company´s proprietary product candidates were generated by CBAS™.
Further information is available at www.affitech.com.
INVESTOR RELATIONS KONTAKT
Director IR & Communications
e-mail:
Senest opdateret 14/2 2011
FINANSIELLE TAL
| DKK’000 | 2010 | 2009 | 2008 |
|---|---|---|---|
| Revenue | 2.395 | 3.538 | 3.807 |
| Research and development costs | -52.269 | -32.940 | -34.018 |
| Administrative expenses | -23.892 | -22.852 | -9.552 |
| Operating profit (EBIT) | -73.766 | -71.436 | -39.763 |
| Other expenses | 6.921 | 1.880 | 2.423 |
| Net financial items | -4.554 | 1.651 | 1.056 |
| Net profit/loss for the year | -71.744 | -67.905 | -36.283 |
| Capital resources ultimo | 81.098 | 2.126 | 9.660 |
| Cash flow from operations | -76.484 | -41.719 | -35.420 |
| Total assets | 116.850 | 34.534 | 17.706 |
| Total equity | 93.304 | 10.148 | 7.901 |
| Total number of shares in thousands | 487.721 | 227,53 | 0.00 |
| BVPS | 0,19 | 0,04 | 0.00 |
| Average number of employees | 34 | 25 | 37 |
Senest opdateret 19/4 2011
Finalize the preclinical development of AT001/r84 and initiate phase I clinical trials with the drug as scheduled in 2011
Forventet: 2011
Forventet: 2011
Select the first drug candidate in the AT008/CCR4 program.
Forventet: 2011
Forventet: 2011
Total operating expenses excluding royalty costs for 2011 are estimated to be in the range of DKK 85-95 million.
Forventet: 2011
Forventet: 2011
Net loss is estimated to be in the range of DKK 45-55 million.
Forventet: 2011
Forventet: 2011
Senest opdateret 20/11 2011
Alexander Duncan
Chief Scientific Officer
Stig Jarle Pettersen
CFO
Senest opdateret 13/4 2011
BEGIVENHEDER
Senest opdateret 24/5 2012
19/4 2012
Senest opdateret 26/4 2012
Aktiekurs for Affitech
Du skal opdatere din Flash Player for at se dette indhold
DINE MULIGHEDER
| Dit kursmål: ingen |
| Gennemsnitligt kursmål (AVG): 0,00 (0) |
| Hvor vil Affitech lukke fra deres nuværende pris? Over  eller under  den nuværende kurs? |
|||
| Om en måned |
Om tre måneder |
Om seks måneder |
Om et år |
|
Brugernes anbefaling
SALG
KØB
|
|||
SKRIV INDLÆG
saving..
;){kind=link}